Tremfya Becomes First IL-23 Inhibitor to Show Spinal Pain Improvement in Axial PsA
JNJ sits 54% above its 52-week low of $175.74.
Summary
J&J's Tremfya met its primary endpoint and major secondary endpoints in the STAR study for axial psoriatic arthritis, including significant improvement in spinal pain and stiffness. This makes it the first IL-23 inhibitor to demonstrate such benefit in axial PsA, a patient population with limited approved options. The safety profile was consistent with prior PsA data with no new signals. The result supports label expansion and could strengthen Tremfya's competitive position against other IL-23 and IL-17 agents. Full data presentation and potential regulatory submissions are the next milestones.
At the time of this announcement, JNJ was trading at $271.28 on NYSE in the Life Sciences sector, with a market capitalization of approximately $652.3B. The 52-week trading range was $175.74 to $281.07. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.